About Us / Investing in America

Investing in America

Since founding the biotechnology industry nearly 50 years ago, Genentech has remained committed to building a strong and innovative presence in America. In April 2025, we made a $50 billion commitment with our parent company, Roche, to help improve our already significant U.S. footprint.

This investment includes new, state-of-the-art R&D and manufacturing facilities, upgrades to existing sites, and the creation of new jobs to support our growing pipeline across our pharmaceutical and diagnostics divisions.

Our Investments, By the Numbers

Behind every number is our commitment to strengthen America’s biopharmaceutical leadership—strengthening innovation, creating jobs, and building the foundation for long-term growth.

  • $50B Commitment in American Infrastructure
  • 27 Manufacturing and R&D Facilities
  • 12K New Jobs

Genentech and Roche are doubling our investment in American infrastructure over the next five years to increase our existing footprint and manufacture 20-25 products, including new pipeline medicines and previously-commercialized medicines manufactured abroad.

  • $5 billion in a new, state-of-the-art research and manufacturing facility
  • $1.4 billion in a new manufacturing facility to support the production of our growing pipeline
  • $2 billion in a global pharmaceutical AI research center
  • $1 billion in a new gene therapy innovation center in Pennsylvania
  • $250 million in a new corporate headquarters
  • Nearly $2 billion in enhancements and improvements to existing facilities across the US over the past 10 years
  • Expanded and upgraded US manufacturing and distribution capabilities for our innovative medicines and diagnostics portfolio in Kentucky, Indiana, New Jersey, Oregon and California
  • A new 700,000 square foot manufacturing centre in Holly Springs, NC to support Genentech and Roche’s expanding portfolio of next generation weight loss medicines

For fifty years, Genentech has invested in America’s scientific and economic strength. Our $50 billion commitment to U.S. manufacturing is the next chapter in that legacy — strengthening our ability to deliver breakthrough medicines made here at home, and reaffirming our commitment to American patients, innovation, and growth.

— Ashley Magargee, CEO of Genentech

News Features

  • Genentech and Roche break ground in Holly Springs, North Carolina

    Genentech broke ground on its newest U.S. manufacturing site in Holly Springs, North Carolina. This significant development marks the establishment of Genentech’s first manufacturing facility on the East Coast.

    Our Business & The Organization

  • Roche and Genentech announce new manufacturing facility

    Genentech announced its plans to invest more than $700 million in a new 700,000 square foot state-of-the-art drug manufacturing facility in Holly Springs, NC.

    Our Business & The Organization

  • Roche to invest USD 50 billion in the US over the next five years

    Roche announced its $50 billion commitment to further strengthen its already significant footprint with 13 manufacturing and 15 R&D sites across the Pharmaceutical and Diagnostics Divisions.

    Our Business & The Organization

© 2025 Genentech, Inc. All rights reserved. This site is intended for US residents only.